0000849636-14-000002.txt : 20140402 0000849636-14-000002.hdr.sgml : 20140402 20140402110003 ACCESSION NUMBER: 0000849636-14-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140402 DATE AS OF CHANGE: 20140402 EFFECTIVENESS DATE: 20140402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CORTEX PHARMACEUTICALS INC/DE/ CENTRAL INDEX KEY: 0000849636 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330303583 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-214715 FILM NUMBER: 14736648 BUSINESS ADDRESS: STREET 1: 126 VALLEY ROAD STREET 2: SUITE C CITY: GLEN ROCK STATE: NJ ZIP: 07452 BUSINESS PHONE: (201) 444-4947 MAIL ADDRESS: STREET 1: 126 VALLEY ROAD STREET 2: SUITE C CITY: GLEN ROCK STATE: NJ ZIP: 07452 D 1 primary_doc.xml X0707 D LIVE 0000849636 CORTEX PHARMACEUTICALS INC/DE/ 126 VALLEY ROAD SUITE C GLEN ROCK NJ NEW JERSEY 07452 (201) 444-4947 DELAWARE None None Corporation true Arnold S. Lippa c/o Cortex Pharmaceuticals, Inc. 126 Valley Road, Suite C Glen Rock NJ NEW JERSEY 07452 Executive Officer Director Biotechnology Decline to Disclose 06b false 2014-03-18 false true true true Convertible Preferred Stock false 1000 Gelband & Co., Inc. 32599 Gelband & Co., Inc. 32599 750 Third Avenue 21st Floor New York NY NEW YORK 10017 NY NEW YORK false Mahoney, Kenneth R. 1911756 Aurora Capital LLC 37924 17 Park Avenue Suite No. 201 New York NY NEW YORK 10016 CA CALIFORNIA CT CONNECTICUT DC DISTRICT OF COLUMBIA FL FLORIDA GA GEORGIA LA LOUISIANA MD MARYLAND NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA PA PENNSYLVANIA VA VIRGINIA false Kelkar, Sachin R. 5191287 Aurora Capital LLC 37924 17 Park Avenue Suite No. 201 New York NY NEW YORK 10016 CA CALIFORNIA FL FLORIDA NY NEW YORK false H.C. Wainright & Co., LLC 375 H.C. Wainright & Co., LLC 375 430 Park Avenue 4th Floor New York NY NEW YORK 10022 All States false 1500000 753220 746780 The maximum amount of this offering is $1,500,000. However, the final amount sold may be less. false 18 46410 true 0 Part of the Sales Commissions set forth above includes common stock warrants, the value of which are estimated. 150000 $150,000 of the gross proceeds of the offering will be used to repay loans to the company by an entity controlled by Mr. Lippa. false CORTEX PHARMACEUTICALS INC/DE/ Arnold S. Lippa Arnold S. Lippa Chairman and Chief Executive Officer 2014-04-01